221 related articles for article (PubMed ID: 10208939)
21. Effects of gag mutations on human immunodeficiency virus type 1 particle assembly, processing, and cyclophilin A incorporation.
Chiu HC; Wang FD; Yao SY; Wang CT
J Med Virol; 2002 Oct; 68(2):156-63. PubMed ID: 12210402
[TBL] [Abstract][Full Text] [Related]
22. Characterization of human immunodeficiency virus type 1 Pr160 gag-pol mutants with truncations downstream of the protease domain.
Liao WH; Wang CT
Virology; 2004 Nov; 329(1):180-8. PubMed ID: 15476885
[TBL] [Abstract][Full Text] [Related]
23. Differential dependence of the infectivity of HIV-1 group O isolates on the cellular protein cyclophilin A.
Wiegers K; Kräusslich HG
Virology; 2002 Mar; 294(2):289-95. PubMed ID: 12009870
[TBL] [Abstract][Full Text] [Related]
24. Molecular recognition in the HIV-1 capsid/cyclophilin A complex.
Yoo S; Myszka DG; Yeh C; McMurray M; Hill CP; Sundquist WI
J Mol Biol; 1997 Jun; 269(5):780-95. PubMed ID: 9223641
[TBL] [Abstract][Full Text] [Related]
25. Obstruction of HIV-1 particle release by interferon-alpha occurs before viral protease processing and is independent of envelope glycoprotein.
Babé LM; Unal A; Craik CS
J Interferon Cytokine Res; 1997 May; 17(5):287-93. PubMed ID: 9181467
[TBL] [Abstract][Full Text] [Related]
26. Maturation-induced conformational changes of HIV-1 capsid protein and identification of two high affinity sites for cyclophilins in the C-terminal domain.
Endrich MM; Gehrig P; Gehring H
J Biol Chem; 1999 Feb; 274(9):5326-32. PubMed ID: 10026140
[TBL] [Abstract][Full Text] [Related]
27. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity.
Sokolskaja E; Sayah DM; Luban J
J Virol; 2004 Dec; 78(23):12800-8. PubMed ID: 15542632
[TBL] [Abstract][Full Text] [Related]
28. The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811.
Dorfman T; Göttlinger HG
J Virol; 1996 Sep; 70(9):5751-7. PubMed ID: 8709190
[TBL] [Abstract][Full Text] [Related]
29. Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative.
Müller B; Daecke J; Fackler OT; Dittmar MT; Zentgraf H; Kräusslich HG
J Virol; 2004 Oct; 78(19):10803-13. PubMed ID: 15367647
[TBL] [Abstract][Full Text] [Related]
30. Fragile X mental retardation protein restricts replication of human immunodeficiency virus type 1.
Pan Q; Rong L; Zhao X; Liang C
Virology; 2009 Apr; 387(1):127-35. PubMed ID: 19249802
[TBL] [Abstract][Full Text] [Related]
31. TRIM5alpha-independent anti-human immunodeficiency virus type 1 activity mediated by cyclophilin A in Old World monkey cells.
Nakayama EE; Shingai Y; Kono K; Shioda T
Virology; 2008 Jun; 375(2):514-20. PubMed ID: 18367226
[TBL] [Abstract][Full Text] [Related]
32. Organization of immature human immunodeficiency virus type 1.
Wilk T; Gross I; Gowen BE; Rutten T; de Haas F; Welker R; Kräusslich HG; Boulanger P; Fuller SD
J Virol; 2001 Jan; 75(2):759-71. PubMed ID: 11134289
[TBL] [Abstract][Full Text] [Related]
33. The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein.
Braaten D; Ansari H; Luban J
J Virol; 1997 Mar; 71(3):2107-13. PubMed ID: 9032343
[TBL] [Abstract][Full Text] [Related]
34. Active-site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions.
Dorfman T; Weimann A; Borsetti A; Walsh CT; Göttlinger HG
J Virol; 1997 Sep; 71(9):7110-3. PubMed ID: 9261445
[TBL] [Abstract][Full Text] [Related]
35. Functional surfaces of the human immunodeficiency virus type 1 capsid protein.
von Schwedler UK; Stray KM; Garrus JE; Sundquist WI
J Virol; 2003 May; 77(9):5439-50. PubMed ID: 12692245
[TBL] [Abstract][Full Text] [Related]
36. Single point mutations in the zinc finger motifs of the human immunodeficiency virus type 1 nucleocapsid alter RNA binding specificities of the gag protein and enhance packaging and infectivity.
Mark-Danieli M; Laham N; Kenan-Eichler M; Castiel A; Melamed D; Landau M; Bouvier NM; Evans MJ; Bacharach E
J Virol; 2005 Jun; 79(12):7756-67. PubMed ID: 15919928
[TBL] [Abstract][Full Text] [Related]
37. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription.
Braaten D; Franke EK; Luban J
J Virol; 1996 Jun; 70(6):3551-60. PubMed ID: 8648689
[TBL] [Abstract][Full Text] [Related]
38. Cells with high cyclophilin A content support replication of human immunodeficiency virus type 1 Gag mutants with decreased ability to incorporate cyclophilin A.
Ackerson B; Rey O; Canon J; Krogstad P
J Virol; 1998 Jan; 72(1):303-8. PubMed ID: 9420228
[TBL] [Abstract][Full Text] [Related]
39. Functional analysis of the secondary HIV-1 capsid binding site in the host protein cyclophilin A.
Peng W; Shi J; Márquez CL; Lau D; Walsh J; Faysal KMR; Byeon CH; Byeon IL; Aiken C; Böcking T
Retrovirology; 2019 Apr; 16(1):10. PubMed ID: 30947724
[TBL] [Abstract][Full Text] [Related]
40. Crystal structure of cyclophilin A complexed with a binding site peptide from the HIV-1 capsid protein.
Vajdos FF; Yoo S; Houseweart M; Sundquist WI; Hill CP
Protein Sci; 1997 Nov; 6(11):2297-307. PubMed ID: 9385632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
